Promoter hypermethylation and loss of CD133 gene expression in colorectal cancers

Table 1 Correlation between promoter methylation status and CD133 expression

Cell lines (32 in total)	M	U	% methylation	% expression
SNU-61	-	-	1	3.1
SNU-81	+	+	4	2.8
SNU-175	++	+	1	19.9
SNU-283	-	+	0	30.7
SNU-407	+	+	1	86.2
SNU-503	++	-	95	2.4
SNU-769A	-	+	3	0.7
SNU-769B	+	++	1	10.2
SNU-1033	-	+	0	14.7
SNU-1040	+	++	0	40.2
SNU-1047	++	+	16	20.3
SNU-1197	+	++	0	2.4
SNU-C1	+	+	3	4.0
SNU-C2A	++	+	29	14.7
SNU-C4	++	++	21	0.5
SNU-C5	+	+	3	3.7
Caco-2	++	-	95	79.6
Colo201	++	++	6	27.4
Colo205	++	-	2	6.8
Colo320	++	+	1	0.7
DLD-1	++	-	21	2.4
HCT-8	++	++	9	1.4
HCT-15	++	+	73	4.7
HCT-116	++	++	31	11.2
HT-29	-	++	0	96.0
LoVo	++	+	14	13.9
LS174T	++	+	53	2.4
NCI-H716	++	++	24	2.6
SW403	+	++	0	19.7
SW480	++	-	64	0.6
SW1116	++	++	10	0.7
WiDr	+	++	0	33.3

M: Methylated CpG site; U: Unmethylated CpG site; -: Not detected; +: Barely detected; ++: Detected; +++: Greatly detected; % methylation: Methylation level of CpGs, (# methylated CpG/# total CpG) × 100; % expression: Relative expression level of CD133 as the ratio to the β-actin expression level, (CD133 level/β-actin level) × 100.